{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:38:27Z","timestamp":1764783507165,"version":"3.37.3"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T00:00:00Z","timestamp":1367884800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0063973","type":"journal-article","created":{"date-parts":[[2013,5,8]],"date-time":"2013-05-08T00:50:40Z","timestamp":1367974240000},"page":"e63973","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics"],"prefix":"10.1371","volume":"8","author":[{"given":"Stacie B.","family":"Dusetzina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina D.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Til","family":"St\u00fcrmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7326\/0003-4819-151-3-200908040-00125","article-title":"Comparative effectiveness research: a report from the Institute of Medicine","volume":"151","author":"HC Sox","year":"2009","journal-title":"Ann oIntern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMp078038","article-title":"Challenges in using observational studies to evaluate adverse effects of treatment","volume":"356","author":"MD Hughes","year":"2007","journal-title":"NEJM"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects","volume":"10","author":"H Petri","year":"1991","journal-title":"Stat Med"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, et al.. (2013) Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf. DOI: 10.1002\/pds.3386<\/ext-link><\/comment>.","DOI":"10.1002\/pds.3386"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/YCO.0b013e328314b74b","article-title":"Addressing cardiometabolic risk during treatment with antipsychotic medications","volume":"21","author":"JM Amiel","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"ref6","unstructured":"F.D.A. U.S. Food and Drug Administration Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News, 2004 Available: http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/psn\/transcript.cfm?show=28#4<\/ext-link>. Accessed 2013 Apr 16."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ps.2008.59.10.1162","article-title":"Changing trends in pediatric antipsychotic use in Florida's Medicaid program","volume":"59","author":"R Constantine","year":"2008","journal-title":"Psychiatr Serv"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archgenpsychiatry.2009.179","article-title":"Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA\/APA recommendations for second-generation antipsychotic drugs","volume":"67","author":"EH Morrato","year":"2010","journal-title":"Arch Gen Psych"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/pds.3272","article-title":"Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory","volume":"21","author":"SB Dusetzina","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, et al.. (2011) Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change. J Clin Psychiatry DOI: 10.4088\/JCP.09m05868yel<\/ext-link><\/comment>.","DOI":"10.4088\/JCP.09m05868yel"},{"key":"ref12","unstructured":"Center for Medicare and Medicaid Services (2007) The Medicaid Analytic Extract Chartbook. Office of Research Development and Information MPR. U.S., Department of Health and Human Services, CMS."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1377\/hlthaff.28.3.649","article-title":"Trends in mental health cost growth: an expanded role for management?","volume":"28","author":"RG Frank","year":"2009","journal-title":"Health affairs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1377\/hlthaff.28.3.746","article-title":"Dual eligibles with mental disorders and Medicare part D: how are they faring?","volume":"28","author":"JM Donohue","year":"2009","journal-title":"Health Aff"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"CE Koro","year":"2002","journal-title":"Arch Gen Psych"},{"key":"ref16","unstructured":"Goode E (2003) 3 Schizophrenia Drugs May Raise Diabetes Risk, Study Says The New York Times. Late Edition \u2013 Final ed. New York: The New York Times."},{"key":"ref17","unstructured":"Anand G, Burton TM (2003) New antipsychotics pose a quandry for FDA, doctors. Wall Street Journal. Available: http:\/\/online.wsj.com\/article\/0,SB105002837738499900,00.html<\/ext-link>. Accessed 2013 Apr 16."},{"key":"ref18","unstructured":"F.D.A. (2004) U.S. Food and Drug Administration, MedWatch Safety Information: Geodon (ziprasidone). MedWatch: The US Food and Drug Administration."},{"key":"ref19","unstructured":"F.D.A. (2005) U.S. Food and Drug Administration, MedWatch Safety Information: Atypical Antipsychotic Drugs."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"JA Lieberman","year":"2005","journal-title":"NEJM"},{"key":"ref21","unstructured":"A.H.C.A. (2005) Florida Agency for Health Care Administration. Agency for Health Care Administration Announces NEW Medicaid Preferred Drug List."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"M Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"ref23","unstructured":"Parsons LS (2001) Reducing bias in propensity score matched-pair sample using greedy matching techniques.; 2001 April 22\u201325, 2001; Long Beach, CA."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"PC Austin","year":"2009","journal-title":"Stat Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"MA Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, et al.. (2012) Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STARD trial data. Pharmacoepidemiol Drug Saf. DOI: 10.1002\/pds.3396<\/ext-link><\/comment>.","DOI":"10.1002\/pds.3396"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0063973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T11:26:18Z","timestamp":1589023578000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0063973"}},"subtitle":[],"editor":[{"given":"Antje","family":"Timmer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,7]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0063973","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2013,5,7]]}}}